16.3
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage requir…
Modified-release drug delivery systems optimize drug therapy by minimizing doses, reducing side effects, and ensuring efficient treatment.
These systems regulate drug release to align with the drug's absorption rate and therapeutic objective.
Drugs having low molecular weights, aqueous solubility above 0.1 mg/mL, and balanced lipophilicity perform best.
Stability is crucial, as drugs unstable in the gastrointestinal tract may require alternative routes like transdermal delivery.
Consistent absorption is vital for effective administration. Oral routes suit stable drugs with doses under 1000 mg, while intramuscular and transdermal routes support extended action or bypass first-pass metabolism.
Pharmacokinetic factors like efficient absorption, an elimination half-life typically between 2 and 4 hours, and consistent metabolism are essential for controlled delivery.
Drugs must also have appropriate pharmacodynamics, including a dose under 1g, a wide therapeutic range, and predictable concentration-response relationships.
View the full transcript and gain access to JoVE Core videos
Q1: What drug properties make a medication suitable for modified-release delivery?
Ideal drugs have low molecular weight, aqueous solubility above 0.1 mg/mL, and balanced lipophilicity for optimal absorption. Stability in the gastrointestinal tract is essential; unstable drugs like nitroglycerin require alternative routes. Dose size under 1 gram and predictable concentration-response relationships further determine suitability for modified-release formulations.
Q2: How does drug half-life influence modified-release system design?
Drugs with elimination half-lives between 2 and 4 hours are ideal candidates for modified-release systems, as seen with propranolol. Drugs with very short half-lives require frequent dosing and may not be suitable. Half-life directly affects how often doses must be administered and whether sustained-release formulations can effectively maintain therapeutic levels.
Q3: Why is the route of administration critical for modified-release drugs?
The route must align with drug properties and therapeutic goals. Oral delivery suits stable drugs with doses under 1000 mg, while transdermal drug delivery systems bypass first-pass metabolism for drugs like nitroglycerin. Intramuscular and parenteral drug delivery systems injectables implants and infusion devices support extended action and overcome absorption limitations.
Q4: What role does therapeutic range play in modified-release drug design?
Drugs with a wide therapeutic range tolerate fluctuations in plasma concentration, while those with narrow therapeutic indices demand precise release control to prevent toxicity. Pharmacodynamic factors including dose size and the concentration-response relationship determine how strictly drug release must be controlled to maintain safety and efficacy.
Q5: How do modified-release systems optimize drug absorption compared to conventional formulations?
In conventional dosage forms, absorption is the limiting step, but in modified-release systems, the rate of drug release from the formulation becomes the key determinant. This controlled release aligns with the drug's pharmacokinetic profile and therapeutic objective, ensuring consistent absorption and minimizing side effects while reducing required doses.
Q6: Why is gastrointestinal stability important for oral modified-release drugs?
Drugs unstable in the gastrointestinal tract cannot maintain consistent absorption through oral delivery, compromising therapeutic effectiveness. Unstable drugs like nitroglycerin require alternative routes such as transdermal administration to ensure reliable drug delivery. Stability assessment is therefore essential before selecting the appropriate administration route.
Q7: What is the relationship between drug lipophilicity and modified-release formulation success?
Lipophilic drugs with high partition coefficients exhibit enhanced absorption and tissue distribution, making them suitable for modified-release systems. Balanced lipophilicity—neither too hydrophilic nor too lipophilic—optimizes drug performance. This property influences both the formulation strategy and the route of administration selected for effective controlled delivery.